Hangzhou Coco Healthcare Products Co., Ltd. Class A

Hangzhou Coco Healthcare Products Co., Ltd. Class A

SSZSE:301009
7.97
CNY
-0.20
(-2.45%)
-0.01EPS
2.51BMarket Cap
Apr 26Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.95
4.56
5.91
8.02
5.07
4.4
3.75
4.15
4.46
4.61
Basic EPS, GAAP
0.21
0.3
0.44
1.05
0.17
-0.16
0.07
0.12
0.14
-0.02
Free Cash Flow per Basic Share
0.16
0.12
0.49
0.86
-0.81
-0.57
0.56
-0.09
0.34
- -
Dividend per Share
0.23
0.01
0.91
0.12
- -
0.07
- -
0.08
0.08
0.13
Book Value per Share
2.16
2.42
1.96
3.01
5.2
4.98
5.05
4.91
4.93
4.77
Tangible Book Value per Share
1.96
2.15
1.7
2.76
4.88
4.66
4.75
4.61
4.6
4.43
Basic Weighted Avg Shares
199
199
199
204
234
270
288
260
258
266
Sales/Revenue/Turnover
787
906
1,174
1,635
1,186
1,186
1,081
1,079
1,150
1,226
Operating Margin (%)
7.5
7.44
100
19.34
3.73
-1.34
1.46
1.76
3.09
1.7
Depreciation Expense
25
30
39
39
49
61
57
59
62
- -
Net Income, GAAP
42
60
87
214
40
-43
20
31
36
-5
Effective Tax Rate (%)
9.79
11.73
13.78
12.27
9.4
- -
8.69
7.11
5.29
- -
Profit Margin (%)
5.32
6.59
7.45
13.09
3.35
-3.64
1.87
2.89
3.14
-0.41
Working Capital
74
99
-38
44
687
684
719
648
690
590
LT Debt
- -
- -
- -
- -
5
3
12
8
5
5
Total Equity
473
536
458
682
1,507
1,432
1,450
1,412
1,421
1,377
Return on Invested Capital (%)
- -
12.04
19.7
36.23
3.59
- -
1.28
1.93
2.4
- -
Return on Capital (%)
- -
11.6
16.46
32.61
3.57
- -
1.6
2.17
2.35
- -
Return on Common Equity (%)
- -
13.06
19.83
42.28
3.92
-3.12
1.48
2.3
2.7
-0.39

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
163
263
264
LT Borrowings
- -
- -
- -
LT Finance Leases
4
5
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
272
272
272
Market Capitalization
3,137
2,221
2,515

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,358
1,392
1,398
Cash, Cash Equivalents & STI
923
982
916
Accounts Receivable, Net
203
192
216
Inventories
143
142
165
Total Current Liabilities
682
767
808
Payables & Accruals
- -
- -
- -
ST Debt
163
263
264
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
23.09%
0.7%
Free Cash Flow
- -
-205.23%
-479.17%
Net Income, GAAP
- -
-73.29%
15.87%
Sales/Revenue/Turnover
- -
-5.98%
6.65%
Total Cash Common Dividend
- -
- -
0.43%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
283
238
268
289
1,079
2025
280
269
- -
321
1,150
2026
291
292
322
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.02
- -
0.03
0.12
2025
0.07
0.04
- -
0.03
0.14
2026
0.01
-0.04
-0.02
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.08
2025
- -
0.07
- -
0.01
0.08
2026
- -
0.12
- -
- -
- -

Company Description

CEO
Li Wei Jin
Full Time Employees
756
Sector
Consumer non-durables
Industry
Household/Personal care
Address
Chengxi Industrial Park Hangzhou ZH China 311300
IPO Date
Jun 17, 2021
Business
Hangzhou Coco Healthcare Products Co., Ltd. (301009.SZ) engages in the research, development, production and sale of disposable hygiene products, primarily baby care, adult incontinence and pet care items, across China and select overseas markets including Asia, Africa, Europe and America. Founded in 2001 and headquartered in Hangzhou, Zhejiang Province, China, the company operates under well-known brands such as COCO and XSB, offering adult incontinence products including adult diapers, pull-up pants, nursing pads, maternity towels, menstrual pants and absorbent towels for men; baby care products such as baby diapers, pull-up pants and wet wipes; pet hygiene products like pet diapers and pads; as well as feminine care, cleaning care, family protection and medical care items. It pursues a dual-drive model of self-owned brands and ODM services, supported by an in-house R&D team, provincial research institutes, over 240 patents and leadership in industry standards for diapers and nursing products. The company listed on the Shenzhen Stock Exchange's ChiNext Board in June 2021, raising approximately RMB 852 million, and signed an equity acquisition intent agreement for a 60% stake in Shanghai Hanhe Paper Co., Ltd. to expand its production capabilities. COCO maintains top market positions, including number one rankings in domestic adult incontinence sales from 2017 to 2022, and holds honors such as national specialized little giant enterprise and top quality benchmarking firm.